Sightline Wealth Advisors LLC Sells 3,307 Shares of Global X Genomics & Biotechnology ETF (NASDAQ:GNOM)

Sightline Wealth Advisors LLC reduced its position in shares of Global X Genomics & Biotechnology ETF (NASDAQ:GNOM) by 5.1% in the fourth quarter, according to its most recent filing with the SEC. The fund owned 61,937 shares of the company’s stock after selling 3,307 shares during the quarter. Sightline Wealth Advisors LLC owned about 0.89% of Global X Genomics & Biotechnology ETF worth $601,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently modified their holdings of GNOM. Atria Investments Inc bought a new position in Global X Genomics & Biotechnology ETF during the third quarter valued at $122,000. Centaurus Financial Inc. purchased a new position in Global X Genomics & Biotechnology ETF in the second quarter worth about $146,000. Rockefeller Capital Management L.P. bought a new stake in Global X Genomics & Biotechnology ETF during the third quarter worth approximately $205,000. James J. Burns & Company LLC raised its position in Global X Genomics & Biotechnology ETF by 6.0% during the third quarter. James J. Burns & Company LLC now owns 18,293 shares of the company’s stock valued at $207,000 after purchasing an additional 1,038 shares during the period. Finally, Sanctuary Advisors LLC purchased a new position in shares of Global X Genomics & Biotechnology ETF in the 2nd quarter worth approximately $590,000. 56.95% of the stock is owned by hedge funds and other institutional investors.

Global X Genomics & Biotechnology ETF Stock Down 1.0 %

GNOM traded down $0.10 during trading on Monday, reaching $9.88. The company had a trading volume of 59,209 shares, compared to its average volume of 64,516. The business has a 50 day simple moving average of $10.28 and a 200-day simple moving average of $10.78. The stock has a market cap of $68.86 million, a P/E ratio of -4.22 and a beta of 1.03. Global X Genomics & Biotechnology ETF has a 52 week low of $9.52 and a 52 week high of $12.53.

Global X Genomics & Biotechnology ETF Profile

Complete Genomics, Inc is a life sciences company that has developed and commercialized a deoxyribonucleic acid (DNA) sequencing platform. Its complete genomics analysis platform (CGA) Platform, combines its human genome sequencing technology with its advanced informatics and data management software and its end-to-end, outsourced service model to provide its customers with data that is ready to be used for genome-based research.